As of a January 2026 legal analysis, BPC-157 remained listed in Category 2, and the compound cannot legally be compounded under sections 503A or 503B of the Food, Drug and Cosmetic Act
GHK-Cu 100mg is not the same type of peptide as BPC-157, but it is an adjacent research compound because it is studied in extracellular matrix, collagen, copper peptide and wound biology models
At the molecular level, BPC-157 has been shown to affect gene expression linked to growth factor signalling, cytoskeletal organisation, and inflammatory response modulation
Curr Drug Metab 13:105119 Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, Sergii G, Petrakova K, Peoples GE (2019) Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial randomized phase III trial of nelipepimut-S in breast cancer
Xray Sci
They're still great